Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy
Cureus · 23.07.2024
DOI: 10.7759/cureus.65163 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cureus, erschienen am 23.07.2024. Verfasst von Lorena Escaño und 1 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine, Danbury Hospital, Danbury, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pembrolizumab is an immune checkpoint inhibitor that blocks the PD1 receptor and is currently used in the treatment of a vast variety of malignancies. Despite adrenal insufficiency already being documented as a rare but potential side effect, its diagnosis is usually delayed due to its vague presentation, increasing the risk of deleterious outcomes. We present a case of secondary adrenal insufficiency while on pembrolizumab, in which the diagnosis was delayed due to a nonspecific clinical picture. This case highlights the importance of maintaining a high index of suspicion for endocrine dysfunction in patients treated with immune checkpoint inhibitors, as early recognition and appropriate intervention are paramount to preventing serious complications in these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine, Danbury Hospital, Danbury, USA.
Zitieren
APA
Escaño, L., & Desai, P. (2024). Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy. Cureus. https://doi.org/10.7759/cureus.65163
Vancouver
Escaño L, Desai P. Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy. Cureus. 2024. doi:10.7759/cureus.65163
BibTeX
@article{Escao2024,
author = {Escaño, Lorena and Desai, Prarthana},
title = {Secondary Adrenal Insufficiency as an Immune-Related Adverse Event of Pembrolizumab Therapy},
journal = {Cureus},
year = {2024},
doi = {10.7759/cureus.65163}
}
EUVIMED